JNJ-4178(AL-335、奥达拉韦与西美瑞韦)治疗无肝硬化丙型肝炎病毒感染患者6周或8周:OMEGA-1研究
OMEGA-1是一项多中心、随机、开放标签IIb期研究,纳入365例无肝硬化的HCV GT1、2、4、5、6型初治或干扰素(±利巴韦林)经治患者,随机接受JNJ-4178方案6周(n=183)或8周(n=182)治疗。6周组SVR12为98.9%,8周组为97.8%,均非劣于历史对照98%;病毒学复发5例(1.4%),大多数不良事件为轻度,无治疗相关严重不良事件。
要点
- 6周组SVR12为98.9%,8周组为97.8%,均非劣于历史对照98%。
- 病毒学复发5例(1.4%),其中4例为HCV GT2c,1例为GT1a。
- 大多数不良事件为轻度,无治疗相关严重不良事件,所有随机患者均完成治疗。
核心结论
- 在HCV感染患者中,JNJ-4178治疗6周和8周分别获得98.9%和97.8%的SVR12率,且耐受性良好。
研究设计与样本
- 多中心、随机、开放标签IIb期研究(NCT02765490),纳入365例无肝硬化的HCV GT1、2、4、5、6型初治或干扰素(±利巴韦林)经治患者,随机接受6周(n=183)或8周(n=182)治疗。
主要发现
- 6周组SVR12为98.9%,8周组为97.8%,均非劣于历史对照98%。
- 病毒学复发5例(1.4%),其中4例为HCV GT2c,1例为GT1a。
- 除8周组4例患者(包括3例SVR24时间点数据缺失)外,所有达到SVR12的患者也达到SVR24。
- 1例GT1a感染患者在达到SVR18后出现晚期病毒学复发。
- 大多数不良事件为轻度,无治疗相关严重不良事件,所有随机患者均完成治疗。
关键数值与推荐
- 患者接受AL-335 800 mg、奥达拉韦25 mg和西美瑞韦75 mg每日一次,治疗6周或8周。
- 主要终点为治疗结束后12周的持续病毒学应答(SVR12)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The combination of three direct-acting antiviral agents (AL-335, odalasvir, and simeprevir: JNJ-4178 regimen) for 6 or 8 weeks demonstrated good efficacy and safety in a phase IIa study in chronic hepatitis C virus (HCV) genotype (GT)-1-infected patients without cirrhosis and has now been evaluated in a larger phase IIb study, OMEGA-1. This multicenter, randomized, open-label study (NCT02765490) enrolled treatment-naïve and interferon (±ribavirin) treatment-experienced patients with HCV GT1, 2, 4, 5, or 6 infection. Patients with HCV GT3 infection and/or liver cirrhosis were excluded. Patients received AL-335 800 mg, odalasvir 25 mg, and simeprevir 75 mg once daily for 6 or 8 weeks. The primary endpoint was sustained virologic response 12 weeks after the end of treatment (SVR12). In total, 365 patients (GT1a, 29.3%; GT1b, 42.5%; GT2, 12.3%; GT4, 14.2%; GT5, 1.4%; GT6, 0%) were randomized to receive 6 weeks (n = 183) or 8 weeks (n = 182) of treatment. SVR12 rates after 6 weeks (98.9%) or 8 weeks (97.8%) of treatment were noninferior to a historical control (98%). Viral relapse occurred in 5 patients (1.4%; 4 with HCV GT2c; 1 with GT1a). With the exception of 4 patients in the 8-week group, including 3 patients with missing data at the SVR24 timepoint, all patients who achieved SVR12 also achieved SVR24. One GT1a-infected patient experienced late viral relapse after achieving SVR18. Most adverse events (AEs) were mild with no treatment-related serious AEs. All randomized patients completed treatment. Conclusion: In HCV-infected patients, 6 and 8 weeks of treatment with JNJ-4178 resulted in SVR12 rates of 98.9% and 97.8%, respectively, and was well tolerated.
引用
- Zeuzem S, Bourgeois S, Greenbloom S, et al. JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1. Hepatology. 2019. PMID: 30693573. doi:10.1002/hep.30527
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。